more low-ball options to the ceo, page-4

Thanks OOPeek, I agree.

I have no reason to dislike Greg or his performance, but after being a VERY patient shareholder, I feel the information has been in part disingenuous. For example, we have NEVER been told the US NDA is essentially void or dead. The last clear indication given (via written word or conference call) was that the NDA was still open and active, however it's obvious now that they expect us to read between the lines and assume it's done with (which it is). Well, in my opinion, that is not genuine or consistent with the responsibilities of a CEO. Mind you, the share price probably could not have dropped anymore if they were to have been more transparent.

Greg is well reimbursed for his hard work and time, but frankly, in terms of share options, if the shareholders suffer, so should the CEO. I thought that was the basic principle of a shareholder/CEO relationship.

And to add insult to the recent injury, the exercise price of 47.5c is ridiculous. And the fact the notice was given a day before our wonderful 2nd epic failure today is very suspicious. Even the title of the press release makes me sick ... "align regulatory strategy". In other words... the questions were the same as the FDA, so let's forget it. Nothing has been said of the so called T315i diagnostic test. For all we know, nothing has been done about it period.

Whilst I admire an Australian company in this field with great potential, it's shocking at the lack of success they have achieved after being handed a drug discovered in the 60's by the Nixon administration, which has been well researched to be effective in CML.

I am voting a NO and I hope everyone whom reads this and feels the same way does too.

Regards,
Nathan